Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the metabolic disease drug market will display robust growth, expanding from $9 billion in 2001 to $14 billion in 2007. This growth is explored in the first of a series of new publications from Decision Resources entitled DR Pipeline Reports. The DR Pipeline Reports reveal the companies with the most clinically effective and commercially viable drug compounds within a therapeutic market. The first report in the series is entitled Pipeline Analysis of Key Players in the Metabolic Disease Market.

"Eli Lilly and Bristol-Myers Squibb dominated the metabolic drug market for diseases such as diabetes (type 1 and type 2) and obesity," said Christine Blazynski, Ph.D, director at Decision Resources. "However, there are emerging players in this market that will garner significant market share by the year 2007. Pfizer, Merck & Co., and Amylin Pharmaceuticals all have pipelines with the potential to grow the market and cut into the major players' current market share."

According to the new DR Pipeline Report, the largest driver for the metabolic disease market is the growth in prevalence of overweight and obese people, as well as those with diabetes.

Geared towards business development decision makers in the pharmaceutical, biotech, and financial industries, the DR Pipeline Reports expose the major companies in a therapeutic market and, more importantly, shed light on the emerging players that could significantly impact the current market once their pipeline compounds are launched.

About DR Pipeline Reports from Decision Resources

DR Pipeline Reports are a series of comprehensive reports that focus on pharmaceutical and biotech company drug development and commercialization strategies. The 2003 Pipeline series reveals which compounds are most clinically effective and commercially viable within five therapeutic markets: major metabolic diseases, psychiatric disorders, gastrointestinal diseases, respiratory diseases, and viral/bacterial infections.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall for Decision Resources, Inc., +1-781-296-
2563, emarshall@dresources.com

Despite Looming Patent Expirations for Several Key Therapies, Steady Growth is Forecasted for the Acute Myocardial Infarction Drug Market

View Now